Infusion timing and outcomes after allogeneic hematopoietic cell transplantation across graft sources
In brief
Allogeneic stem cell grafts infused before 4 pm show no outcome advantage
In a retrospective study of 1,714 transplant recipients, grafts infused before 4 pm were not linked to better survival, fewer serious complications, or faster blood count recovery than later infusions, across three graft sources. The findings do not support changing afternoon workflows to move infusions earlier, but whether morning infusion matters remains unknown.
- Journal
- Transplantation and cellular therapy (Q1)
- Published
- 6 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Shuhei Kurosawa, Tomomi Toubai, Atsushi Jinguji, Naoki Shingai, Takashi Toya, Kaoru Morita, et al.
- PMID
- 42994756
- DOI
- 10.1016/j.jtct.2026.11.007
Why clinicians should know about it
- Picked for Hematology (paper of the day, 12 November 2026): Transplant infusion timing and allogeneic HCT outcomes
Abstract
BACKGROUND: Circadian regulation can shape immune activation and has been linked to outcomes after immunotherapy and cellular therapies. In allogeneic hematopoietic cell transplantation (allo-HCT), whether graft infusion time influences graft-versus-host disease (GVHD), non-relapse mortality (NRM), or hematopoietic recovery remains uncertain, and prior clinical studies have largely focused on single graft sources. OBJECTIVE(S): To determine whether clock time of graft infusion is associated with transplant outcomes after allo-HCT and whether these associations differ among bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), and cord blood transplantation (CBT). STUDY DESIGN: We retrospectively analyzed 1,714 consecutive patients aged 16 years or older who underwent first allo-HCT at our institution from 2004 through 2025. Patients were stratified by graft source. Infusion time was defined as the recorded graft-product release time from the transfusion service to the transplant ward. Based on the institutional infusion-time distribution, infusions before 16:00 were classified as Early and those at or after 16:00 as Late. Propensity score matching was performed separately within each graft source, and inverse probability of treatment weighting (IPTW) was used as a complementary analysis. The primary endpoint was 5-year NRM. Secondary endpoints included overall survival, progression-free survival, relapse, neutrophil and platelet engraftment, and acute GVHD. RESULTS: The cohort included 1,008 BMT, 478 PBSCT, and 228 CBT recipients. Propensity score matching generated 242, 172, and 63 Early-Late pairs, respectively. Five-year NRM for Early vs. Late infusion was 18.3% (95% confidence interval [CI], 13.1-23.1) vs. 19.4% (95% CI, 14.2-24.4) after BMT (P = 0.78), 20.7% (95% CI, 13.6-27.1) vs. 26.4% (95% CI, 18.5-33.5) after PBSCT (P = 0.23), and 16.4% (95% CI, 5.6-26.1) vs. 17.8% (95% CI, 6.8-27.5) after CBT (P = 0.88). Fifty-day neutrophil engraftment was similar after BMT (95.5% [95% CI, 92.6-97.2] vs. 94.8% [95% CI, 91.8-96.8]; P = 0.62), PBSCT (97.1% [95% CI, 94.1-98.6] vs. 96.2% [95% CI, 92.8-98.0]; P = 0.47), and CBT (81.6% [95% CI, 70.0-88.7] vs. 79.7% [95% CI, 67.6-87.2]; P = 0.75). The 100-day cumulative incidence of grade II-IV acute GVHD also did not differ significantly after BMT (37.6% [95% CI, 31.2-43.4] vs. 43.3% [95% CI, 36.8-49.2]; P = 0.20), PBSCT (32.5% [95% CI, 25.2-39.1] vs. 30.2% [95% CI, 23.0-36.7]; P = 0.65), or CBT (35.9% [95% CI, 23.1-46.6] vs. 33.7% [95% CI, 20.9-44.3]; P = 0.79). IPTW analyses showed no significant association between Late infusion and NRM, survival, relapse, engraftment, or acute GVHD across the three graft sources. CONCLUSION(S): In this graft source-stratified cohort, earlier infusion across the 16:00 threshold was not associated with improved outcomes. These findings do not support routinely changing graft handling or infusion workflows solely to achieve earlier infusion within the afternoon range. The potential benefit of morning infusion remains to be determined.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.